Pharmacotherapy for Alcohol Use Disorder (AUD)
Pharmacotherapy for Alcohol Use Disorder (AUD) is organized by Providers Clinical Support System (PCSS).
Release Date: 11/10/2023
Expiration Date: 01/12/2026.
Description:
Alcohol use disorder (AUD) is commonly encountered in clinical settings, and FDA-approved medications are available. This module reviews and compares pharmacological treatments for individuals with AUD, including acamprosate, disulfiram, and naltrexone (oral and long-acting intramuscular formulations), as well as non-approved (off-label) options including topiramate and gabapentin. Diagnosis of AUD and definitions of binge drinking and “at risk” drinking levels (per US Dietary Guidelines) are discussed. Effects of alcohol use on the brain, including neurotransmitter effects and withdrawal symptoms, are also reviewed. The module concludes with a discussion of a case vignette in which medication options for AUD are considered.
Educational Objectives:
• Explain how to establish a diagnosis for Alcohol Use Disorder (AUD)
• Assess the rationale for using pharmacotherapy for AUD
• Describe dosing and mechanism of action for the following medications:
• FDA-approved (naltrexone, acamprosate, disulfiram)
• Off-label (topiramate, gabapentin)
• Identify AUD pharmacotherapy options through a case vignette
Additional Details Will Be Posted as Soon as Information is Available.